Thr538
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr538  -  PKCT (human)

Site Information
LGDAktNtFCGtPDy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447907
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 25 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ) , mutation of modification site ( 26 , 36 ) , phospho-antibody ( 1 , 3 , 16 , 24 , 26 , 27 , 35 , 36 ) , western blotting ( 3 , 16 , 24 , 35 , 36 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , lung cancer ( 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 20 , 21 , 34 ) , non-small cell lung cancer ( 8 , 9 , 10 , 12 , 13 , 14 , 20 , 21 ) , non-small cell lung cancer, surrounding tissue ( 22 ) , non-small cell lung adenocarcinoma ( 4 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , non-small cell large cell lung carcinoma ( 9 , 12 ) , non-small cell squamous cell lung carcinoma ( 11 ) , small-cell lung cancer ( 6 , 7 ) , pancreatic cancer ( 3 ) , pancreatic carcinoma ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 35 ) , A549 (pulmonary) ( 8 ) , breast ( 2 ) , BxPC-3 (pancreatic) ( 3 ) , Cal-12T (pulmonary) ( 14 ) , Calu-3 (pulmonary) ( 10 ) , DMS153 (pulmonary) ( 13 ) , DMS53 (pulmonary) ( 7 ) , DMS79 (pulmonary) ( 6 ) , HCC15 (pulmonary) ( 11 ) , HCC44 (pulmonary) ( 14 ) , HCC78 (pulmonary) ( 12 ) , HCC827 (pulmonary) ( 10 ) , HEK293T (epithelial) ( 36 ) , hUCB-MSCs ( 1 ) , Jurkat (T lymphocyte) ( 15 , 16 , 17 , 18 , 19 , 24 , 25 , 26 , 27 , 36 ) , K562 (erythroid) ( 23 ) , liver ( 5 ) , LOU-NH91 (squamous) ( 11 ) , lung ( 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 20 , 21 , 22 ) , NCI-H128 (pulmonary) ( 6 ) , NCI-H1299 (pulmonary) ( 9 ) , NCI-H1355 (pulmonary) ( 8 ) , NCI-H1417 (pulmonary) ( 6 ) , NCI-H1437 (pulmonary) ( 13 , 14 ) , NCI-H1650 (pulmonary) ( 10 ) , NCI-H1666 (pulmonary) ( 14 ) , NCI-H1703 (squamous) ( 11 ) , NCI-H1734 (pulmonary) ( 9 ) , NCI-H1781 (pulmonary) ( 12 ) , NCI-H1792 (pulmonary) ( 8 ) , NCI-H1944 (pulmonary) ( 9 ) , NCI-H1975 (pulmonary) ( 10 ) , NCI-H2073 (pulmonary) ( 11 , 13 ) , NCI-H209 (pulmonary) ( 6 , 13 ) , NCI-H2106 (pulmonary) ( 10 ) , NCI-H2228 (pulmonary) ( 12 ) , NCI-H23 (pulmonary) ( 8 ) , NCI-H2342 (pulmonary) ( 11 ) , NCI-H2405 (pulmonary) ( 14 ) , NCI-H3122 (pulmonary) ( 12 ) , NCI-H358 (pulmonary) ( 9 ) , NCI-H441 (pulmonary) ( 8 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ) , NCI-H446 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 9 ) , NCI-H524 (pulmonary) ( 6 ) , NCI-H526 (pulmonary) ( 7 ) , NCI-H661 (pulmonary) ( 12 ) , NCI-H69 (pulmonary) ( 7 ) , NCI-H82 (pulmonary) ( 7 ) , NCI-H838 (pulmonary) ( 13 ) , PC9 (pulmonary) ( 4 )

Upstream Regulation
Regulatory protein:
SLP76 (human) ( 16 )
Putative in vivo kinases:
KHS2 (human) ( 16 )
Kinases, in vitro:
KHS2 (human) ( 16 )
Treatments:
AH6809 ( 3 ) , anti-CD3 ( 16 ) , anti-CD3/CD28 ( 27 ) , anti-CD38 ( 24 ) , GW627368X ( 3 ) , hyaluronan ( 24 ) , hypoxia ( 1 ) , IGF-1 ( 3 ) , phorbol_ester ( 27 , 35 ) , salicylate ( 35 ) , siRNA ( 16 )

Downstream Regulation
Effects of modification on PKCT:
enzymatic activity, induced ( 26 , 36 )
Effects of modification on biological processes:
signaling pathway regulation ( 16 ) , transcription, altered ( 36 )

Disease / Diagnostics Relevance
Relevant diseases:
SLE ( 16 )

References 

1

Han KH, et al. (2017) Protein profiling and angiogenic effect of hypoxia-cultured human umbilical cord blood-derived mesenchymal stem cells in hindlimb ischemia. Tissue Cell 49, 680-690
28958480   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Takahashi T, et al. (2015) Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: Involvement of protein kinase C-θ activation. Oncotarget 6, 4829-44
25638159   Curated Info

4

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

5

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

16

Chuang HC, et al. (2011) The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells. Nat Immunol 12, 1113-8
21983831   Curated Info

17

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

18

Guo A (2011) CST Curation Set: 11891; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

19

Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

20

Rikova K (2010) CST Curation Set: 9450; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

21

Rikova K (2010) CST Curation Set: 9215; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

22

Rikova K (2009) CST Curation Set: 8543; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

23

Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

24

Muñoz P, et al. (2008) Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 111, 3653-64
18212246   Curated Info

25

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info

26

Thuille N, et al. (2005) Critical role of novel Thr-219 autophosphorylation for the cellular function of PKCtheta in T lymphocytes. EMBO J 24, 3869-80
16252004   Curated Info

27

Freeley M, Volkov Y, Kelleher D, Long A (2005) Stimulus-induced phosphorylation of PKC theta at the C-terminal hydrophobic-motif in human T lymphocytes. Biochem Biophys Res Commun 334, 619-30
16009340   Curated Info

28

Moritz A (2005) CST Curation Set: 792; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

29

Moritz A (2005) CST Curation Set: 793; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

30

Moritz A (2005) CST Curation Set: 794; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

31

Moritz A (2005) CST Curation Set: 797; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

32

Moritz A (2005) CST Curation Set: 799; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

33

Moritz A (2005) CST Curation Set: 783; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

34

Moritz A (2005) CST Curation Set: 706; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

35

Jiang G, et al. (2003) Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. J Biol Chem 278, 180-6
12409308   Curated Info

36

Liu Y, et al. (2002) Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-kappaB induction. Biochem J 361, 255-65
11772397   Curated Info